U.S. markets closed
  • S&P 500

    4,401.46
    -20.84 (-0.47%)
     
  • Dow 30

    35,058.52
    -85.79 (-0.24%)
     
  • Nasdaq

    14,660.58
    -180.14 (-1.21%)
     
  • Russell 2000

    2,191.83
    -25.09 (-1.13%)
     
  • Crude Oil

    71.89
    -0.02 (-0.03%)
     
  • Gold

    1,798.80
    -0.40 (-0.02%)
     
  • Silver

    24.72
    -0.60 (-2.38%)
     
  • EUR/USD

    1.1822
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • GBP/USD

    1.3882
    +0.0058 (+0.42%)
     
  • USD/JPY

    109.7540
    -0.6210 (-0.56%)
     
  • BTC-USD

    38,400.99
    +1,484.57 (+4.02%)
     
  • CMC Crypto 200

    898.78
    +22.55 (+2.57%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

What Is The Ownership Structure Like For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)?

·4 min read

The big shareholder groups in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

With a market capitalization of US$775m, Arcturus Therapeutics Holdings is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about Arcturus Therapeutics Holdings.

View our latest analysis for Arcturus Therapeutics Holdings

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Arcturus Therapeutics Holdings?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Arcturus Therapeutics Holdings already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Arcturus Therapeutics Holdings' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Arcturus Therapeutics Holdings. The company's largest shareholder is ARK Investment Management LLC, with ownership of 13%. With 12% and 8.4% of the shares outstanding respectively, Federated Hermes, Inc. and Ultragenyx Pharmaceutical Inc. are the second and third largest shareholders. In addition, we found that Joseph Payne, the CEO has 5.6% of the shares allocated to their name.

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Arcturus Therapeutics Holdings

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

I can report that insiders do own shares in Arcturus Therapeutics Holdings Inc.. It has a market capitalization of just US$775m, and insiders have US$74m worth of shares, in their own names. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public holds a 11% stake in Arcturus Therapeutics Holdings. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Public Company Ownership

It appears to us that public companies own 8.4% of Arcturus Therapeutics Holdings. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Arcturus Therapeutics Holdings , and understanding them should be part of your investment process.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.